Search Results
Your search for ,kEY matches 7151 pages
Showing 3251 - 3300Study Examines Socioeconomic Status and Cervical Cancer Incidence in New York City
In a study reported in a research letter in JAMA Oncology, Cham et al found that cervical cancer incidence increased with decreasing socioeconomic status index scores across neighborhoods in New York City (NYC). Study Details The population-based, cross-sectional study included data on women...
European OnCovid Registry Analysis of Time-Dependent COVID-19 Mortality in Patients With Cancer
As reported in JAMA Oncology by researchers from the OnCovid Study Group, an updated analysis of the European OnCovid registry indicated that mortality due to COVID-19 infection has decreased over time for patients with cancer during the pandemic. Study Details The study included real-world data on ...
Immune Checkpoint Inhibitor Treatment in Patients Aged 65 and Older With Advanced Melanoma: Association Between Sex and Survival
In a study reported in JAMA Network Open, Jang et al found that women with advanced melanoma receiving combination immune checkpoint inhibitor therapy with nivolumab/ipilimumab as their most recent immune checkpoint inhibitor therapy (all with prior ipilimumab treatment) had a poorer survival...
The National Cancer Act of 1971
On December 23, 1971, President Richard M. Nixon signed the National Cancer Act into law. At that time, cancer was the nation’s second leading cause of death; only about one of two people diagnosed with cancer survived at least 5 years—compared with two of three people diagnosed with the disease...
Erudition and Assessment on the Longest War in the Modern Era
A little after noon on December 23, 1971, President Richard Nixon entered the White House state dining room. Before 137 esteemed guests from government, science, and industry, he signed the landmark National Cancer Act. It was, in short, a national commitment to conquer cancer. President Nixon...
The History of Medical Oncology in Europe, 1955–1985
In part 1 of this two-part review, we looked at early pioneers in the field of medical oncology in Europe, as well as the development of international cooperative trials and the formation of European oncology societies (see related articles below). In part 2, we explore how the field of medical...
Three Investigators Named Winners of MSK Cancer Center’s 2021 Paul Marks Prize for Cancer Research
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three recipients of this year’s Paul Marks Prize for Cancer Research. The prize recognizes a new generation of leaders in cancer research who are making significant contributions to the understanding of cancer or are improving the...
Newer Cancer Therapies Offer Hope but Also May Confer Cardiac Risk
Since many different chemotherapeutic agents have been linked with cardiac adverse events, there is a growing need for strategies for the assessment and mitigation of treatment-induced cardiotoxicity. Moreover, the rapid rise of immunotherapies has added a new dimension to this clinical setting....
Cancer Researcher and Biotech Founder Lewis Cantley, PhD, Joins Dana-Farber
Lewis Cantley, PhD, the cancer researcher best known for his discovery of the PI3K pathway and his groundbreaking work on cancer metabolism, will be joining the Dana-Farber Cancer Institute in February 2022. Dr. Cantley’s move from his current position as Director of the Sandra and Edward Meyer...
Tara O. Henderson, MD, MPH, to Lead Programs at UChicago Medicine, Chicagoland Children’s Health
Tara O. Henderson, MD, MPH, has been named the new Service Line Chief of Pediatric Cancer and Blood Diseases at the Chicagoland Children’s Health Alliance (CCHA), a collaboration between University of Chicago Medicine Comer Children’s Hospital, Advocate Children’s Hospital, and Pediatrics at...
Profiles of Cancer Risk Associated With Immune-Mediated Diseases
In a study reported in JAMA Oncology, He et al found that individuals with immune-mediated diseases were at an increased risk of developing cancer, with organ-specific immune-mediated diseases being more strongly associated with local vs extralocal cancers. Study Details The prospective cohort...
Association of TP53 Gain-of-Function and Non–Gain-of-Function Mutations With Outcomes in Left-Sided vs Right-Sided Metastatic Colorectal Cancer
In a study reported in the Journal of Clinical Oncology, Pan et al found that overall survival was poorer among patients with metastatic right-sided vs left-sided colorectal cancer with TP53 mutations, driven by poorer outcomes in those with non–gain-of-function mutations, and that gain-of-function ...
Long-Term Outcomes From CheckMate 067: Nivolumab/Ipilimumab, Nivolumab, or Ipilimumab in Advanced Melanoma
In a 6.5-year update of the phase III CheckMate 067 trial reported in the Journal of Clinical Oncology, Jedd D. Wolchok, MD, PhD, FASCO, and colleagues provided long-term overall survival as well as melanoma-specific survival findings among patients with advanced melanoma who received nivolumab...
Use of Adjuvant Chemotherapy in Older Patients With Pancreatic Cancer and Its Effect on Overall Survival
In a study reported in JAMA Oncology, Mehtsun et al found patterns of increasing use of adjuvant chemotherapy over time among patients aged ≥ 80 years undergoing pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. In addition, they found that use of adjuvant chemotherapy was associated...
Telemedicine Use Among U.S. Patients With Newly Diagnosed Cancer: Impact of Socioeconomic Status
In a study reported in a research letter in JAMA Oncology, Katz et al found that higher socioeconomic status was associated with greater use of telemedicine among patients with newly diagnosed cancers in the United States between January and August 2020. As stated by the investigators, “The...
COVID-19 Infection After SARS–CoV-2 Messenger RNA Vaccination in Patients With Cancer
In a study reported in JAMA Oncology, Wu et al found that vaccination with SARS–CoV-2 messenger RNA vaccines reduced the incidence of COVID-19 infection vs no vaccination in Veterans Affairs (VA) patients with cancer. Vaccine effectiveness varied according to time between last systemic therapy and...
I-SPY2 Study Finds Tumor Biology Is a More Significant Factor Than Race in Predicting Response to Breast Cancer Treatment
Data analysis from the I-SPY2 clinical trial found that among women with high-risk breast cancer, race did not significantly affect several key measures of breast cancer treatment outcomes, including pathologic complete response (pCR) and event-free survival. The study, which is being presented by...
Fully Vaccinated Patients With Multiple Myeloma: Rates of SARS–CoV-2 Breakthrough Infection and Hospitalization
In a U.S. cohort study reported in JAMA Network Open, Wang et al found that fully vaccinated patients with multiple myeloma were at increased risk of breakthrough SARS–CoV-2 infection, and that those with breakthrough infection were more likely to be hospitalized vs fully vaccinated persons without ...
KEYNOTE-355 Final Analysis Reveals Survival Benefit With Pembrolizumab in Triple-Negative Breast Cancer
The final overall survival results from the KEYNOTE-355 study showed a statistically significant 27% reduction in the risk of death for patients with metastatic triple-negative breast cancer whose tumors were strongly positive for PD-L1, defined as a combined positive score (CPS) of at least 10 and ...
Response to Third Dose of SARS–CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment
In a single-institution Israeli study reported in a research letter in JAMA Oncology, Rottenberg et al found that a booster dose of the SARS–CoV-2 BNT162b2 mRNA resulted in increased spike protein antibody titers in patients with solid tumors undergoing active treatment. Study Details The study...
Association of Donor Clonal Hematopoiesis With Outcomes in Hematopoietic Stem Cell Transplant Recipients
In a study reported in the Journal of Clinical Oncology, Gibson et al identified significant associations of donor clonal hematopoiesis with outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation (HCT). As stated by the investigators, “Clonal hematopoiesis can be...
Managing Illness Expectations in Patients With Advanced Cancer
In a study reported in JCO Oncology Practice, Sigler et al found that an oncology nurse–led primary palliative care intervention known as CONNECT did not increase realistic illness expectations among patients with advanced cancer. Study Details The study involved adults with advanced solid tumors...
Trends in Incidence of Colorectal Cancer Among Black and White Individuals Aged 40 to 49 Years From 2000 to 2017
In a study reported in JAMA Network Open, Montminy et al found that the incidence of colorectal adenocarcinoma in people aged 40 to 49 years in the United States has increased in White individuals and remained stable in Black individuals between 2000 and 2017, with incidence rates being equivalent...
Study Examines the Effect of Breast MRI on Short-Term Quality of Life in Women With DCIS
In a substudy of the ECOG-ACRIN E4112 cohort trial reported in JAMA Network Open, Fazeli et al found that approximately half of women with ductal carcinoma in situ (DCIS) undergoing magnetic resonance imaging (MRI) for pretreatment planning experienced fear or anxiety before and during the...
COG AAML1331 Trial: Arsenic Trioxide and All-Trans Retinoic Acid in Pediatric Patients With APL
As reported in JAMA Oncology by Kutny et al, the Children’s Oncology Group (COG) AAML1331 trial has shown that treatment with arsenic trioxide and all-trans retinoic acid (ATRA) with no maintenance therapy produced high event-free and overall survival rates in pediatric patients with acute...
Cancer Incidence and Patterns in Individuals With Pathogenic/Likely Pathogenic Germline TP53 Variants
In an observational cohort study reported in The Lancet Oncology, de Andrade et al identified cancer incidence and patterns in individuals meeting criteria for Li-Fraumeni syndrome on the basis of presence of pathogenic or likely pathogenic germline TP53 variants. As stated by the investigators,...
Response to SARS–CoV-2 mRNA Vaccination in Patients With B-Cell Depletion Associated With CAR T-Cell Therapy
In a small single-institution study reported in a research letter in JAMA Oncology, Parvathaneni et al found that SARS–CoV-2 mRNA vaccination produced antibody responses in nearly half—and CD4 T-cell responses in more than half—of patients with B-cell depletion due to treatment with...
Emily Z. Keung, MD, on Interactions of Sarcoma, Immune Infiltrates, and Checkpoint Blockade
Emily Z. Keung, MD, of The University of Texas MD Anderson Cancer Center, discusses the complex interactions of immune infiltrates and neoadjuvant immune checkpoint blockade (ICB) in patients with resectable soft-tissue sarcoma. These interactions may hold the key to understanding pathologic...
Cancer-Related Financial Toxicity: Role of Race
In a study reported in JCO Oncology Practice, Panzone et al found that compared to White patients with a history of cancer, Black patients and ‘other race’ patients—but not Hispanic patients—were significantly more likely to have experienced financial toxicity due to cancer. Study Details The...
Phase II Breast Cancer Trial: Large Declines in Ki67 Index Seen With Oral Selective Estrogen Receptor Degrader
In the phase II coopERA Breast Cancer trial, which evaluated two endocrine neoadjuvant therapies in estrogen receptor–positive, HER2-negative early breast cancer, the oral selective estrogen receptor degrader giredestrant led to a greater reduction in Ki67 level—a measure of cancer cell...
Impact of Prior Blinatumomab Exposure on CD19-Targeted CAR T-Cell Therapy Outcomes in Pediatric Patients With B-Cell ALL
In a study reported in the Journal of Clinical Oncology, Myers et al found that lack of response to prior blinatumomab treatment was associated with poorer outcomes with CD19-targeted chimeric antigen receptor (CAR) T-cell therapy (CD19-CAR) in children and young adults with relapsed or refractory...
Addressing the Global Challenges of Cancer Prevention and Treatment
Nearly 20 million people around the world were diagnosed with cancer in 2020, with 10 million losing their lives to this devastating disease. We highlight here the salient points from our article published in CA: A Cancer Journal for Clinicians,1 which describes the major themes and...
Study Examines Treatment-Related Regret Among Men With Localized Prostate Cancer
In a prospective cohort study (CEASAR) reported in JAMA Oncology, Wallis et al found that patient expectations of treatment efficacy and adverse effects were associated with treatment-related regret at 5 years after diagnosis in men with localized prostate cancer. As stated by the investigators,...
Impact of Time of Day of Immune Checkpoint Inhibitor Infusion on Overall Survival in Patients With Metastatic Melanoma
In a single-institution study reported in The Lancet Oncology, Qian et al found that the administration of immune checkpoint inhibitors after 4:30 PM was associated with poorer overall survival vs infusion earlier in the day in patients with metastatic melanoma. As stated by the investigators, “The ...
Research Letter Examines Changes in Cancer Mortality 50 Years After Passage of the National Cancer Act
In a study reported in a research letter in JAMA Oncology, Kratzer et al found that mortality from cancer overall has decreased significantly since the passage of the National Cancer Act in 1971, with reductions observed in 12 of the 15 cancer sites associated with the highest mortality rates in...
SARC Appoints Jonathan Fletcher, MD, to New Role of Chief Scientific Officer
Sarcoma Alliance for Research Through Collaboration (SARC) recently announced the appointment of Jonathan Fletcher, MD, as Chief Scientific Officer (CSO). This is a new role at the nonprofit cancer research organization, a leader in collaborative discovery, translational research, and clinical...
Maintenance Daratumumab After Initial Therapy for Transplant-Eligible Multiple Myeloma: More Questions Than Answers From CASSIOPEIA Part 2
Bortezomib, thalidomide, and dexamethasone (VTd) is an acceptable, effective standard-of-care induction treatment in Europe for patients with newly diagnosed myeloma who are eligible for autologous stem cell transplantation. CASSIOPEIA is a two-part, open-label, randomized, phase III trial in...
Five Percent Overall Medicare Reimbursement Cut Estimated for Medical Oncology in 2022
On November 2, 2021, the Centers for Medicare & Medicaid Services (CMS) released the 2022 Medicare Physician Fee Schedule (PFS) and Quality Payment Program (QPP) final rule. Although ASCO will analyze the rule in greater detail in the coming days, initial highlights from the rule are outlined...
Northwell Names Fidel Valea, MD, to Leadership Roles in Gynecologic Oncology
Fidel Valea, MD, recently announced his appointment as System Chief of Gynecologic Oncology at Northwell Health and Director of Gynecologic Oncology at the Northwell Health Cancer Institute. He will see patients in New Hyde Park, New York, and Manhattan. In his role as System Chief of Gynecologic...
Achieving Equity in Cancer Care for Adolescents and Young Adults With Cancer
Although cancer in adolescents and young adults (AYAs), defined by the National Cancer Institute as those between the ages of 15 and 39, is relatively rare—in 2020 nearly 90,000 AYAs were diagnosed with cancer and about 9,300 died of the disease1—and 5-year relative survival rates are high, between ...
Adjuvant Immunotherapy: The Next Chapter in Advancements in Renal Cell Carcinoma
Renal cell carcinoma is a common malignancy among men and women in the United States.1 The incidence continues to increase with the ever-increasing use of contemporary medical imaging. Although many patients who present with localized disease are cured with definitive surgery, some patients develop ...
KEYNOTE-564 Trial: Adjuvant Pembrolizumab Improves Disease-Free Survival in High-Risk Renal Cell Carcinoma
As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and colleagues, an interim analysis of the phase III KEYNOTE-564 trial has showed improved disease-free survival with adjuvant pembrolizumab vs placebo after nephrectomy in high-risk...
High-Risk Multiple Myeloma: Combination Regimens and CAR T-Cell Therapy
“Continuous improvement is better than delayed perfection.” —Mark Twain To complement The ASCO Post’s extensive coverage of the 2021 ASCO Annual Meeting, here are several abstracts selected from the meeting proceedings focusing on novel treatments under study in high-risk multiple myeloma. For...
T-DXd Makes Inroads in the Treatment of HER2-Mutant NSCLC
Previously treated patients with HER2-positive non–small cell lung cancer (NSCLC) achieved encouraging response rates and duration of response to the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) in the phase II DESTINY-Lung01 trial. These results were reported at the European...
In Case You Missed It: Brief Highlights From ESMO Congress 2021
The ASCO Post has published a wealth of practice-changing studies and news about other advances presented during the European Society for Medical Oncology (ESMO) Congress 2021. In addition to the biggest news from this international meeting, here are several summaries of interesting study findings...
Can SBRT to Selected Sites of Limited Progression or Oligoprogression Extend Progression-Free Survival in Advanced Lung Cancer but Not Breast Cancer?
Stereotactic body radiation therapy (SBRT) lengthens progression-free survival for patients with advanced lung cancer who have oligoprogression (ie, tumors that have not been fully responsive to systemic chemotherapy or immunotherapy), according to an interim analysis of the CURB oligoprogression...
Study Finds Unique Genomic and Molecular Features in Young Adult Patients With Cancer
Young adults diagnosed with cancer may require different treatments than those received by older patients, according to a study that systematically compared the genomes of 14 different types of cancers affecting both younger and older adults. The results, published by Lee et al in Cell Reports,...
Shorter-Course Radiation Therapy: A New Practice Standard After Prostatectomy?
Hypofractionated radiotherapy to the prostate bed proved to be noninferior to conventionally fractionated radiotherapy after prostatectomy regarding gastrointestinal and genitourinary side effects, according to the results of the phase III NRG Oncology GU003 trial, presented at the 2021 American...
AI-Based Breast Cancer Risk Model: Multi-institution Validation
In a study reported in the Journal of Clinical Oncology, Yala et al found that using the artificial intelligence (AI)-based Mirai model across diverse populations resulted in consistently accurate predictions of breast cancer risk based on screening mammography. Study Details In the study, Mirai...
2021 State of Lung Cancer Report Finds Survival Has Increased but Remains Significantly Lower for People of Color
The new 2021 State of Lung Cancer report reveals that the 5-year survival rate for lung cancer increased from 14.5% nationally to 23.7%, yet it remains significantly lower among communities of color. The American Lung Association’s fourth annual report also highlights how the toll of lung cancer...
